CoChat

Defining the molecular pathology of pancreatic body and tail adenocarcinoma

Open access
Australian Pancreatic Cancer Genome Initiative, Dreyer, S B, Jamieson, N B, Upstill-Goddard, R, Bailey, P J, McKay, C J, Biankin, A V, Chang, D K · 2018 · British Journal of Surgery
Cited by 122

The DOI matches its Crossref record; 9 of the 9 references it cites were found in a registry or an index.

Abstract

Background: Pancreatic ductal adenocarcinoma (PDAC) remains a dismal disease, with very little improvement in survival over the past 50 years. Recent large-scale genomic studies have improved understanding of the genomic and transcriptomic landscape of the disease, yet very little is known about molecular heterogeneity according to tumour location in the pancreas; body and tail PDACs especially tend to have a significantly worse prognosis. The aim was to investigate the molecular differences between PDAC of the head and those of the body and tail of the pancreas. Methods: Detailed correlative analysis of clinicopathological variables, including tumour location, genomic and transcriptomic data, was performed using the Australian Pancreatic Cancer Genome Initiative (APGI) cohort, part of the International Cancer Genome Consortium study. Results: Clinicopathological data were available for 518 patients recruited to the APGI, of whom 421 underwent genomic analyses; 179 of these patients underwent whole-genome and 96 RNA sequencing. Patients with tumours of the body and tail had significantly worse survival than those with pancreatic head tumours (12·1 versus 22·0 months; P = 0·001). Location in the body and tail was associated with the squamous subtype of PDAC. Body and tail PDACs enriched for gene programmes involved in tumour invasion and epithelial-to-mesenchymal transition, as well as features of poor antitumour immune response. Whether this is due to a molecular predisposition from the outset, or reflects a later time point on the tumour molecular clock, requires further investigation using well designed prospective studies in pancreatic cancer. Conclusion: PDACs of the body and tail demonstrate aggressive tumour biology that may explain worse clinical outcomes.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1002/bjs.10772

Cites

9 of 9 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 9 references

Research works printed but not linked: 21

  1. Garrido-Laguna, 2015, Pancreatic cancer: from state-of-the-art treatments to promising novel therapies, Nat Rev Clin Oncol, 12, 319, 10.1038/nrclinonc.2015.53 · DOI · Paper page
  2. Neoptolemos, 2017, Comparison of adjuvant gemcitabine and capecitabine with gemcitabine monotherapy in patients with resected pancreatic cancer (ESPAC-4): a multicentre, open-label, randomised, phase 3 trial, Lancet, 389, 1011, 10.1016/S0140-6736(16)32409-6 · DOI · Paper page
  3. Artinyan, 2008, The anatomic location of pancreatic cancer is a prognostic factor for survival, HPB (Oxford), 10, 371, 10.1080/13651820802291233 · DOI · Paper page
  4. Brennan, 1996, Management of adenocarcinoma of the body and tail of the pancreas, Ann Surg, 223, 506, 10.1097/00000658-199605000-00006 · DOI · Paper page
  5. Watanabe, 2004, Onset symptoms and tumor locations as prognostic factors of pancreatic cancer, Pancreas, 28, 160, 10.1097/00006676-200403000-00007 · DOI
  6. Sener, 1999, Pancreatic cancer: a report of treatment and survival trends for 100 313 patients diagnosed from 1985–1995, using the National Cancer Database, J Am Coll Surg, 189, 1, 10.1016/S1072-7515(99)00075-7 · DOI · Paper page
  7. Lau, 2010, Incidence and survival of pancreatic head and body and tail cancers: a population-based study in the United States, Pancreas, 39, 458, 10.1097/MPA.0b013e3181bd6489 · DOI · Paper page
  8. Sohn, 2000, Resected adenocarcinoma of the pancreas – 616 patients: results, outcomes, and prognostic indicators, J Gastrointest Surg, 4, 567, 10.1016/S1091-255X(00)80105-5 · DOI · Paper page
  9. Jones, 2008, Core signaling pathways in human pancreatic cancers revealed by global genomic analyses, Science, 321, 1801, 10.1126/science.1164368 · DOI · Paper page
  10. Collisson, 2011, Subtypes of pancreatic ductal adenocarcinoma and their differing responses to therapy, Nat Med, 17, 500, 10.1038/nm.2344 · DOI · Paper page
  11. Fang, 2017, Genomic signatures of pancreatic adenosquamous carcinoma (PASC), J Pathol, 243, 155, 10.1002/path.4943 · DOI
  12. Hoadley, 2014, Multiplatform analysis of 12 cancer types reveals molecular classification within and across tissues of origin, Cell, 158, 929, 10.1016/j.cell.2014.06.049 · DOI · Paper page
  13. Li, 2009, Fast and accurate short read alignment with Burrows–Wheeler transform, Bioinformatics, 25, 1754, 10.1093/bioinformatics/btp324 · DOI · Paper page
  14. Bland, 2004, The logrank test, BMJ, 328, 1073, 10.1136/bmj.328.7447.1073 · DOI · Paper page
  15. Cox, 1972, Regression models and life-tables, J R Stat Soc B, 34, 187, 10.1111/j.2517-6161.1972.tb00899.x · DOI · Paper page
  16. Groot, 2017, Patterns, timing, and predictors of recurrence following pancreatectomy for pancreatic ductal adenocarcinoma
  17. Kuhlmann, 2017, Identification and validation of novel subtype-specific protein biomarkers in pancreatic ductal adenocarcinoma, Pancreas, 46, 311, 10.1097/MPA.0000000000000743 · DOI
  18. Noll, 2016, CYP3A5 mediates basal and acquired therapy resistance in different subtypes of pancreatic ductal adenocarcinoma, Nat Med, 22, 278, 10.1038/nm.4038 · DOI · Paper page
  19. Biankin, 2009, Expression of S100A2 calcium-binding protein predicts response to pancreatectomy for pancreatic cancer, Gastroenterology, 137, 558, 10.1053/j.gastro.2009.04.009 · DOI
  20. Chang, 2011, A molecular prognostic nomogram for resectable pancreatic cancer, J Clin Oncol, 29, 154, 10.1200/jco.2011.29.4_suppl.154 · doi:10.1200/jco.2011.29.4_suppl.154
  21. Steele, 2016, CXCR2 inhibition profoundly suppresses metastases and augments immunotherapy in pancreatic ductal adenocarcinoma, Cancer Cell, 29, 832, 10.1016/j.ccell.2016.04.014 · DOI · Paper page

Cited by

Metadata

Authors
Initiative, A. P. C. G., Dreyer, S. B., Jamieson, N. B., Upstill-Goddard, R., Bailey, P. J., McKay, C. J., Biankin, A. V., & Chang, D. K.
Venue
British Journal of Surgery
Published
2018-01
Volume
105
Issue
2
Pages
e183-e191
ISSN
  • 0007-1323 (ISSN-L)
  • 1365-2168
OpenAlex
W2784433219
Cited by
122
References
9
FWCI
5.65
Type
journal article
Language
en
Open access
hybrid

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.